Home LiteratureArticle Details
PMID: 21390033 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Beyond natural antibodies: the power of in vitro display technologies.

Nature biotechnology ·Vol. 29 ·No. 3 ·2011-03-00 ·Pages 245-54

Bradbury AR, Sidhu S, Dübel S, McCafferty J

Abstract

In vitro display technologies, best exemplified by phage and yeast display, were first described for the selection of antibodies some 20 years ago. Since then, many antibodies have been selected and improved upon using these methods. Although it is not widely recognized, many of the antibodies derived using in vitro display methods have properties that would be extremely difficult, if not impossible, to obtain by immunizing animals. The first antibodies derived using in vitro display methods are now in the clinic, with many more waiting in the wings. Unlike immunization, in vitro display permits the use of defined selection conditions and provides immediate availability of the sequence encoding the antibody. The amenability of in vitro display to high-throughput applications broadens the prospects for their wider use in basic and applied research.

MeSH Terms
Antibodies, Monoclonal/chemistry,metabolism Biotechnology/trends Drug Design Peptide Library
Chemicals
Antibodies, Monoclonal Peptide Library
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bradbury Andrew R M
Los Alamos National Laboratory, Los Alamos, New Mexico, USA. amb@lanl.gov
Sidhu Sachdev
Dübel Stefan
McCafferty John
References (177)
177 references, click to expand
  1. Comparative specificity of antisera raised against estrone, estradiol-17 and estriol using 6-0-carboxy-methyloxime bovine serum albumin derivatives.
    Steroids. 1973 May;21(5):755-69 PMID: 4735844
  2. Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein.
    J Immunol Methods. 2007 Apr 10;321(1-2):60-9 PMID: 17336997
  3. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.
    Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12467-72 PMID: 15306681
  4. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
    Science. 2009 Mar 20;323(5921):1610-4 PMID: 19299620
  5. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen.
    Biotechnology (N Y). 1994 Sep;12(9):899-903 PMID: 7521646
  6. Therapeutic antibodies elicited by immunization against TNF-alpha.
    Nat Biotechnol. 1999 Jul;17(7):666-9 PMID: 10404159
  7. A surface expression vector for antibody screening.
    Gene. 1991 Aug 15;104(2):147-53 PMID: 1916287
  8. Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library.
    Proc Natl Acad Sci U S A. 1989 Aug;86(15):5728-32 PMID: 2503822
  9. Improving the affinity and the fine specificity of an anti-cortisol antibody by parsimonious mutagenesis and phage display.
    J Immunol. 1998 Nov 15;161(10):5421-9 PMID: 9820517
  10. A human scFv antibody generation pipeline for proteome research.
    J Biotechnol. 2011 Apr 10;152(4):159-70 PMID: 20883731
  11. Phage antibodies: filamentous phage displaying antibody variable domains.
    Nature. 1990 Dec 6;348(6301):552-4 PMID: 2247164
  12. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.
    J Mol Biol. 1995 Dec 1;254(3):392-403 PMID: 7490758
  13. Human single-chain Fv antibodies against Burkholderia mallei and Burkholderia pseudomallei.
    Exp Biol Med (Maywood). 2007 Apr;232(4):550-6 PMID: 17392491
  14. Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv.
    Nat Biotechnol. 1997 Aug;15(8):768-71 PMID: 9255792
  15. Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies.
    Adv Ther. 2010 Jul;27(7):458-75 PMID: 20574692
  16. High avidity scFv multimers; diabodies and triabodies.
    J Immunol Methods. 1999 Dec 10;231(1-2):177-89 PMID: 10648937
  17. Antibodies to steroids from a small human naive IgM library.
    FEBS Lett. 1997 Sep 1;414(1):7-13 PMID: 9305722
  18. A microengraving method for rapid selection of single cells producing antigen-specific antibodies.
    Nat Biotechnol. 2006 Jun;24(6):703-7 PMID: 16699501
  19. Phage-displayed antibody fragments recognizing dengue 3 and dengue 4 viruses as tools for viral serotyping in sera from infected individuals.
    Arch Virol. 2009;154(7):1035-45 PMID: 19504165
  20. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library.
    Virol J. 2008 Oct 28;5:130 PMID: 18957074
  21. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!
    J Neurosci Methods. 2008 Jun 15;171(1):78-86 PMID: 18406468
  22. Synthetic antibodies for specific recognition and crystallization of structured RNA.
    Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):82-7 PMID: 18162543
  23. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate.
    Immunity. 1998 Jun;8(6):751-9 PMID: 9655489
  24. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.
    Curr Pharm Biotechnol. 2008 Dec;9(6):482-501 PMID: 19075687
  25. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    PLoS One. 2008;3(12):e3942 PMID: 19079604
  26. Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific.
    Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):409-12 PMID: 18989658
  27. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule.
    Infect Immun. 1984 Sep;45(3):604-9 PMID: 6205994
  28. De novo production of diverse intracellular antibody libraries.
    Nucleic Acids Res. 2003 Mar 1;31(5):e23 PMID: 12595572
  29. Antibody validation.
    Biotechniques. 2010 Mar;48(3):197-209 PMID: 20359301
  30. An antibody library for stabilizing and crystallizing membrane proteins - selecting binders to the citrate carrier CitS.
    FEBS Lett. 2004 Apr 30;564(3):340-8 PMID: 15111119
  31. Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display.
    Protein Eng Des Sel. 2010 Apr;23(4):279-88 PMID: 20164216
  32. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
    Arthritis Rheum. 2003 Nov;48(11):3253-65 PMID: 14613291
  33. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.
    J Mol Biol. 2004 Jul 23;340(5):1073-93 PMID: 15236968
  34. A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.
    BMC Biotechnol. 2007 Nov 22;7:81 PMID: 18034894
  35. Computational design of antibody-affinity improvement beyond in vivo maturation.
    Nat Biotechnol. 2007 Oct;25(10):1171-6 PMID: 17891135
  36. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS.
    J Mol Biol. 2003 Nov 14;334(1):103-18 PMID: 14596803
  37. Some ascites monoclonal antibody preparations contain contaminants that bind to selected Golgi zones or mast cells.
    J Histochem Cytochem. 1994 Feb;42(2):213-21 PMID: 7507139
  38. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.
    Nat Biotechnol. 2003 Feb;21(2):163-70 PMID: 12536217
  39. Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection.
    AIDS Res Hum Retroviruses. 2008 Mar;24(3):367-73 PMID: 18327984
  40. Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids.
    Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4337-42 PMID: 19246393
  41. Microscale characterization of the binding specificity and affinity of a monoclonal antisulfotyrosyl IgG antibody.
    Electrophoresis. 2008 Jun;29(12):2557-64 PMID: 18494034
  42. Glycosylation engineering in yeast: the advent of fully humanized yeast.
    Curr Opin Biotechnol. 2007 Oct;18(5):387-92 PMID: 17951046
  43. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
    J Biol Chem. 2006 Jan 13;281(2):951-61 PMID: 16278208
  44. Antibody-based vascular tumor targeting.
    Recent Results Cancer Res. 2010;180:201-16 PMID: 20033385
  45. Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy.
    Immunotechnology. 1999 Mar;4(3-4):273-8 PMID: 10231096
  46. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries.
    Gene. 1997 Mar 10;187(1):9-18 PMID: 9073061
  47. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding.
    FEBS Lett. 1999 Jun 18;453(1-2):164-8 PMID: 10403395
  48. Recombinant antibodies to the small GTPase Rab6 as conformation sensors.
    Science. 2003 May 9;300(5621):984-7 PMID: 12738866
  49. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens.
    J Mol Biol. 2010 Nov 19;404(1):88-99 PMID: 20851130
  50. Engineered proteins as specific binding reagents.
    Curr Opin Biotechnol. 2005 Aug;16(4):459-69 PMID: 16005204
  51. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    J Mol Biol. 1996 Nov 8;263(4):551-67 PMID: 8918938
  52. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
    Cancer Res. 1996 Jul 1;56(13):3055-61 PMID: 8674062
  53. An open letter to our readers on the use of antibodies.
    J Comp Neurol. 2005 Dec 26;493(4):477-8 PMID: 16304632
  54. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
    Mol Cancer Ther. 2007 Oct;6(10):2737-46 PMID: 17938267
  55. Directing phage selections towards specific epitopes.
    Protein Eng. 1996 Nov;9(11):1043-9 PMID: 8961357
  56. Fine tuning of an anti-testosterone antibody binding site by stepwise optimisation of the CDRs.
    Immunotechnology. 1998 Jun;4(1):59-69 PMID: 9661815
  57. Breaking the affinity ceiling for antibodies and T cell receptors.
    Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10679-81 PMID: 11005851
  58. Intracellular immunization with cytosolic recombinant antibodies.
    Biotechnology (N Y). 1994 Apr;12(4):396-9 PMID: 7764686
  59. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.
    J Immunol Methods. 2001 Feb 1;248(1-2):17-30 PMID: 11223066
  60. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.
    Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50 PMID: 12177434
  61. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
    Proc Natl Acad Sci U S A. 1998 May 26;95(11):6037-42 PMID: 9600913
  62. Antibodies from phage antibody libraries.
    J Immunol Methods. 2004 Jul;290(1-2):29-49 PMID: 15261570
  63. Fluorogen-activating single-chain antibodies for imaging cell surface proteins.
    Nat Biotechnol. 2008 Feb;26(2):235-40 PMID: 18157118
  64. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.
    Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3137-41 PMID: 7724529
  65. Antisera highly specific for 17 -oestradiol.
    Steroids. 1971 Nov;18(5):605-20 PMID: 5149575
  66. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.
    PLoS One. 2010 Aug 17;5(8):e12237 PMID: 20808925
  67. Tumor targeting using anti-her2 immunoliposomes.
    J Control Release. 2001 Jul 6;74(1-3):95-113 PMID: 11489487
  68. The fibronectin type III domain as a scaffold for novel binding proteins.
    J Mol Biol. 1998 Dec 11;284(4):1141-51 PMID: 9837732
  69. An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.
    Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11011-5 PMID: 19549879
  70. Alternative non-antibody scaffolds for molecular recognition.
    Curr Opin Biotechnol. 2007 Aug;18(4):295-304 PMID: 17643280
  71. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
    Nat Struct Mol Biol. 2009 Mar;16(3):265-73 PMID: 19234466
  72. Selection of antibodies for intracellular function using a two-hybrid in vivo system.
    Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11723-8 PMID: 10518517
  73. Antigen-independent selection of stable intracellular single-chain antibodies.
    FEBS Lett. 2001 Nov 23;508(3):407-12 PMID: 11728462
  74. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding.
    Cell. 1995 Oct 20;83(2):323-31 PMID: 7585949
  75. pSKAP/S: An expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins.
    Protein Expr Purif. 1999 Jun;16(1):63-9 PMID: 10336861
  76. Targeted tumor therapies at a glance.
    Curr Drug Targets. 2009 Feb;10(2):89-93 PMID: 19199903
  77. A novel immunization procedure for production of anti-testosterone and anti-5 alpha-dihydrotestosterone antisera of low cross-reactivity.
    J Steroid Biochem. 1980 Aug;13(8):951-9 PMID: 7464141
  78. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target.
    Nat Methods. 2007 Mar;4(3):269-79 PMID: 17327848
  79. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin.
    Mol Immunol. 2000 Dec;37(17):1067-77 PMID: 11399324
  80. Antibody-based targeting of the tumor vasculature.
    Biochim Biophys Acta. 2007 Dec;1776(2):175-92 PMID: 17920773
  81. By-passing immunization. Human antibodies from V-gene libraries displayed on phage.
    J Mol Biol. 1991 Dec 5;222(3):581-97 PMID: 1748994
  82. Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework.
    J Biol Chem. 2002 Nov 22;277(47):45075-85 PMID: 12215438
  83. Application of phage display to high throughput antibody generation and characterization.
    Genome Biol. 2007;8(11):R254 PMID: 18047641
  84. Intracellular immunization: antibody targeting to subcellular compartments.
    Trends Cell Biol. 1995 Jun;5(6):248-52 PMID: 14732130
  85. Detection of sulfur mustard adducts in human callus by phage antibodies.
    Chem Biol Drug Des. 2007 May;69(5):314-20 PMID: 17539823
  86. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Hum Antibodies. 1999;9(1):23-36 PMID: 10331183
  87. Automated screening procedure for high-throughput generation of antibody fragments.
    Biotechniques. 2002 Dec;Suppl:30-7 PMID: 12514927
  88. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.
    Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10701-5 PMID: 10984501
  89. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region.
    Infect Immun. 2005 Dec;73(12):8362-8 PMID: 16299334
  90. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.
    J Cell Biol. 2005 Mar 14;168(6):863-8 PMID: 15767460
  91. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.
    Blood. 2006 Nov 1;108(9):3103-11 PMID: 16840730
  92. Engineering novel binding proteins from nonimmunoglobulin domains.
    Nat Biotechnol. 2005 Oct;23(10):1257-68 PMID: 16211069
  93. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    J Clin Oncol. 2000 Apr;18(8):1622-36 PMID: 10764422
  94. Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies.
    J Immunol Methods. 2009 Feb 28;341(1-2):30-40 PMID: 19038261
  95. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
    J Mol Med (Berl). 2007 Oct;85(10):1113-23 PMID: 17554518
  96. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.
    J Biol Chem. 1998 Aug 21;273(34):21769-76 PMID: 9705314
  97. Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody.
    J Biol Chem. 2006 Dec 8;281(49):37877-87 PMID: 17046811
  98. Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat.
    Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5241-6 PMID: 11959974
  99. Construction of intergeneric hybrids using bacteriophage P1CM: transfer of the Klebsiella aerogenes ribitol dehydrogenase gene to Escherichia coli.
    J Bacteriol. 1976 Feb;125(2):728-38 PMID: 1107331
  100. Current constructs and targets in clinical development for antibody-based cancer therapy.
    Curr Drug Targets. 2009 Feb;10(2):158-75 PMID: 19199912
  101. Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries.
    J Immunol Methods. 2004 Apr;287(1-2):31-47 PMID: 15099754
  102. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
    Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118 PMID: 12183061
  103. The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3.
    Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9637-42 PMID: 9275175
  104. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
    Int J Cancer. 2008 Jun 1;122(11):2405-13 PMID: 18271006
  105. High-throughput screening of single-chain antibodies using multiplexed flow cytometry.
    J Proteome Res. 2007 Mar;6(3):1072-82 PMID: 17330944
  106. Bispecific antibodies for cancer immunotherapy: Current perspectives.
    BioDrugs. 2010 Apr 1;24(2):89-98 PMID: 20199124
  107. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood.
    Nat Med. 2009 Sep;15(9):1088-92 PMID: 19684583
  108. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.
    Science. 1985 Jun 14;228(4705):1315-7 PMID: 4001944
  109. Towards proteome scale antibody selections using phage display.
    N Biotechnol. 2010 May 31;27(2):118-28 PMID: 19883803
  110. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli.
    Science. 1988 May 20;240(4855):1038-41 PMID: 3285470
  111. Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice.
    Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):389-95 PMID: 18974978
  112. Green fluorescent antibodies: novel in vitro tools.
    Protein Eng. 2000 Jun;13(6):445-52 PMID: 10877856
  113. An efficient route to human bispecific IgG.
    Nat Biotechnol. 1998 Jul;16(7):677-81 PMID: 9661204
  114. Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis.
    J Immunol Methods. 2003 May 1;276(1-2):185-96 PMID: 12738372
  115. Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein.
    Structure. 2005 Aug;13(8):1131-41 PMID: 16084385
  116. Antibodies in haystacks: how selection strategy influences the outcome of selection from molecular diversity libraries.
    J Immunol Methods. 2001 Jul 1;253(1-2):233-42 PMID: 11384684
  117. Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies.
    J Biol Chem. 2008 Dec 19;283(51):36031-8 PMID: 18955492
  118. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.
    Nat Biotechnol. 2002 Jun;20(6):597-601 PMID: 12042864
  119. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody.
    Immunity. 1997 Jun;6(6):727-38 PMID: 9208845
  120. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display.
    Nat Biotechnol. 2000 Dec;18(12):1287-92 PMID: 11101809
  121. Coiling of intermediate filaments induced by microinjection of a vimentin-specific antibody does not interfere with locomotion and mitosis.
    Eur J Cell Biol. 1981 Dec;26(1):83-90 PMID: 7198976
  122. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
    Nat Biotechnol. 2007 Jan;25(1):107-16 PMID: 17173035
  123. Isolating and engineering human antibodies using yeast surface display.
    Nat Protoc. 2006;1(2):755-68 PMID: 17406305
  124. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv).
    J Immunol Methods. 1995 Jan 27;178(2):201-9 PMID: 7836782
  125. Two-state selection of conformation-specific antibodies.
    Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3071-6 PMID: 19208804
  126. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.
    J Mol Biol. 2005 Aug 5;351(1):158-69 PMID: 16002090
  127. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003.
    Virology. 2010 Feb 20;397(2):322-30 PMID: 19969317
  128. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
    Mov Disord. 2004 Mar;19 Suppl 8:S101-8 PMID: 15027061
  129. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 PMID: 17062691
  130. Generating recombinant antibodies to the complete human proteome.
    Trends Biotechnol. 2010 Jul;28(7):333-9 PMID: 20538360
  131. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.
    Protein Eng. 1996 Jul;9(7):617-21 PMID: 8844834
  132. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library.
    J Biol Chem. 1996 Mar 29;271(13):7630-4 PMID: 8631798
  133. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies.
    Protein Eng. 1999 Jul;12(7):597-604 PMID: 10436086
  134. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex.
    Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10338-42 PMID: 8816801
  135. Multimerization domains for antibody phage display and antibody production.
    N Biotechnol. 2009 Dec 31;26(6):314-21 PMID: 19631299
  136. The evolution of titer and specificity of aldosterone binding antibodies in hyperimmunized sheep.
    Steroids. 1972 Jul;20(1):73-88 PMID: 5065023
  137. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.
    Infect Immun. 1999 Jun;67(6):2957-63 PMID: 10338505
  138. Automated panning and screening procedure on microplates for antibody generation from phage display libraries.
    J Biomol Screen. 2009 Mar;14(3):282-93 PMID: 19224869
  139. Yeast surface display for screening combinatorial polypeptide libraries.
    Nat Biotechnol. 1997 Jun;15(6):553-7 PMID: 9181578
  140. Phage display systems and their applications.
    Appl Microbiol Biotechnol. 2006 Mar;70(1):2-11 PMID: 16365766
  141. Crystal structure of full-length KcsA in its closed conformation.
    Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6644-9 PMID: 19346472
  142. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3.
    J Biol Chem. 2008 Mar 21;283(12):8046-54 PMID: 18182388
  143. Therapeutic antibody targeting of individual Notch receptors.
    Nature. 2010 Apr 15;464(7291):1052-7 PMID: 20393564
  144. Engineering the steroid-specificity of an anti-17beta-estradiol Fab by random mutagenesis and competitive phage panning.
    Protein Eng. 1998 Feb;11(2):143-52 PMID: 9605549
  145. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen.
    Mol Immunol. 2007 Apr;44(10):2749-55 PMID: 17210180
  146. Selection of tumor-specific internalizing human antibodies from phage libraries.
    J Mol Biol. 2000 Sep 1;301(5):1149-61 PMID: 10966812
  147. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
    MAbs. 2009 Nov-Dec;1(6):552-62 PMID: 20068388
  148. Human antibodies from immunized donors are protective against anthrax toxin in vivo.
    Nat Biotechnol. 2003 Nov;21(11):1305-6 PMID: 14555959
  149. Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
    J Biol Chem. 1994 Sep 30;269(39):23931-6 PMID: 7929040
  150. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context.
    Mol Cell Proteomics. 2006 Dec;5(12):2350-63 PMID: 16971384
  151. Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.
    MAbs. 2009 May-Jun;1(3):288-96 PMID: 20069756
  152. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.
    J Exp Med. 2000 Apr 17;191(8):1395-412 PMID: 10770805
  153. From rodent reagents to human therapeutics using antibody guided selection.
    Methods. 2005 May;36(1):61-8 PMID: 15848075
  154. Identification of scFv antibody fragments that specifically recognise the heroin metabolite 6-monoacetylmorphine but not morphine.
    J Immunol Methods. 2003 Sep;280(1-2):139-55 PMID: 12972195
  155. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells.
    Nat Biotechnol. 2010 Sep;28(9):965-9 PMID: 20802495
  156. Crystal structure of a diabody, a bivalent antibody fragment.
    Structure. 1994 Dec 15;2(12):1217-26 PMID: 7704531
  157. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries.
    J Mol Biol. 2007 Nov 2;373(4):924-40 PMID: 17825836
  158. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model.
    Lab Invest. 2007 Mar;87(3):251-60 PMID: 17260003
  159. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens.
    Protein Eng Des Sel. 2009 Mar;22(3):159-68 PMID: 18974080
  160. Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules.
    Nat Protoc. 2007;2(12):3063-73 PMID: 18079705
  161. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
    J Mol Recognit. 2003 Sep-Oct;16(5):324-32 PMID: 14523945
  162. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
    Proc Natl Acad Sci U S A. 1989 May;86(10):3833-7 PMID: 2726754
  163. In vitro selection of a high affinity antibody to oestradiol using a phage display human antibody library.
    Immunotechnology. 1996 Sep;2(3):209-17 PMID: 9373313
  164. Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins.
    J Biol Chem. 2005 Jul 1;280(26):24715-22 PMID: 15851475
  165. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library.
    Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2682-7 PMID: 11226299
  166. The Sulfinator: predicting tyrosine sulfation sites in protein sequences.
    Bioinformatics. 2002 May;18(5):769-70 PMID: 12050077
  167. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda.
    Science. 1989 Dec 8;246(4935):1275-81 PMID: 2531466
  168. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction.
    Biochem Biophys Res Commun. 1989 May 15;160(3):1250-6 PMID: 2499327
  169. Effector mechanisms of therapeutic antibodies against ErbB receptors.
    Curr Opin Immunol. 2008 Aug;20(4):436-43 PMID: 18585454
  170. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses.
    PLoS One. 2009;4(5):e5476 PMID: 19421326
  171. Kinetics in interactions between antibodies and haptens.
    Biochemistry. 1975 Apr 8;14(7):1496-1502 PMID: 1168488
  172. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV).
    BMC Biotechnol. 2008 Sep 02;8:66 PMID: 18764933
  173. Searching for peptide ligands with an epitope library.
    Science. 1990 Jul 27;249(4967):386-90 PMID: 1696028
  174. A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold.
    J Mol Biol. 2001 Jul 13;310(3):603-15 PMID: 11439027
  175. Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay.
    Virology. 2002 Sep 1;300(2):236-43 PMID: 12350354
  176. Molecular engineering and design of therapeutic antibodies.
    Curr Opin Immunol. 2008 Aug;20(4):460-70 PMID: 18656541
  177. Intrabodies as therapeutic agents.
    Methods. 2004 Oct;34(2):163-70 PMID: 15312669
Article Info
Journal
Nature biotechnology
Abbr.
Nat Biotechnol
ISSN
1546-1696
DOI
10.1038/nbt.1791
Email
amb@lanl.gov
Published
2011-03-00
Pages
245-54
Language
English
Region
United States
NLM ID
9604648
PMCID
PMC3057417
Subset
IM
Grants
NIGMS NIH HHS · P50GM085273 · United States
Wellcome Trust · United Kingdom
NHGRI NIH HHS · R01-HG004852-01A1 · United States
NIGMS NIH HHS · P50 GM085273 · United States
NHGRI NIH HHS · R01 HG004852 · United States
NIGMS NIH HHS · P50 GM085273-02 · United States
External Links
PubMed source DOI: 10.1038/nbt.1791 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2